- Durata Therapeutics (DRTX +1.8%) subsidiary Durata Therapeutics International B.V. enters into a license and supply agreement with Angelini to commercialize dalbavancin in 36 countries, including Russia, Italy, Spain and Poland.
- Under the terms of the agreement, Durata will receive an upfront payment of $15M and another payment of $10M upon EMA approval. It will also be eligible for milestone payments and royalties on sales.
- The MAA for dalbavancin is currently under EMA review. A decision is expected in 1H 2015.
From other sites
at Benzinga.com (Dec 31, 2014)
at CNBC.com (Oct 6, 2014)
at MarketWatch.com (Oct 6, 2014)
at CNBC.com (Aug 4, 2014)
at MarketWatch.com (May 27, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs